Table 2 Adverse events experienced by at least 10% of patients (N = 21) with multiplicities within a patient eliminated by selecting the AE with the maximum grade
Adverse Event | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 | Frequency (%) |
|---|---|---|---|---|---|---|---|
Fatigue | 2 | 1 | 1 | 2 | 2 | 4 | 12 (57.1) |
Headache | 1 | 2 | 1 | 1 | 1 | 4 | 10 (47.6) |
Diarrhea | 1 | 1 | 2 | 0 | 0 | 1 | 5 (23.8) |
Dizziness | 1 | 0 | 2 | 0 | 0 | 2 | 5 (23.8) |
Edema cerebral | 0 | 1 | 1 | 0 | 1 | 2 | 5 (23.8) |
Gait disturbance | 0 | 2 | 1 | 0 | 2 | 0 | 5 (23.8) |
Seizure | 1 | 1 | 0 | 1 | 1 | 1 | 5 (23.8) |
Alanine aminotransferase increased | 1 | 1 | 1 | 0 | 1 | 0 | 4 (19) |
Anorexia | 0 | 0 | 0 | 2 | 1 | 0 | 3 (14.3) |
Aspartate aminotransferase increased | 1 | 1 | 1 | 0 | 0 | 0 | 3 (14.3) |
Constipation | 0 | 1 | 1 | 0 | 0 | 1 | 3 (14.3) |
Dysesthesia | 0 | 0 | 0 | 1 | 1 | 1 | 3 (14.3) |
Dysphasia | 1 | 0 | 0 | 1 | 0 | 1 | 3 (14.3) |
Edema limbs | 0 | 1 | 0 | 2 | 0 | 0 | 3 (14.3) |
Generalized muscle weakness | 0 | 1 | 0 | 1 | 0 | 1 | 3 (14.3) |
Memory impairment | 0 | 0 | 0 | 0 | 0 | 3 | 3 (14.3) |
Muscle weakness lower limb | 1 | 1 | 1 | 0 | 0 | 0 | 3 (14.3) |
Nausea | 0 | 1 | 1 | 0 | 0 | 1 | 3 (14.3) |
Tinnitus | 1 | 1 | 1 | 0 | 0 | 0 | 3 (14.3) |
Vomiting | 1 | 0 | 1 | 0 | 0 | 1 | 3 (14.3) |
